Liver Diseases B

Product(bictegravir 50mg/emtricitabine 200mg/tenaforvir alafenamide 25mg) is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those

00:00 / 00:00

Jun 30, 2022, UK-RDA-1234

BIKTARVY (bictegravir 50mg/emtricitabine 200mg/tenaforvir alafenamide 25mg) is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those

Liver Diseases C

Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxl fumarate (TDF), and may occur with discontinuation of product.

00:00 / 00:00

Jun 18, 2022, UK-RDA-1234

Descovy® is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg. DESCOVY is also indicated, in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 25 kg and less than 35 kg.